Adjuvant therapy in melanoma

Impact: Health impacts


I have been closely involved with a number of major initiatives that have defined the standard of care and new treatments for high risk melanoma. these have ranged from being senior investigator on a large phase 3 trial, key contributor to published individual patient data meta-analysis, key contributor to pivotal clinical trials, submitted grant application to CRUL for new biomarker driven trial ansd developing further new international trial with EORTC and Pharma.

Category of impact

  • Health impacts
1 Jan 2015